Search results
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 21 hours agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Missouri Independent via Yahoo News· 4 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Park National Corp OH
ETF DAILY NEWS· 2 days agoPark National Corp OH lowered its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 17.7% during the first quarter, according to its most recent disclosure with the Securities and ...
Johnson & Johnson (NYSE:JNJ) Shares Sold by Smith Shellnut Wilson LLC ADV
ETF DAILY NEWS· 5 days agoSmith Shellnut Wilson LLC ADV decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.6% in the fourth quarter, according to its most recent Form 13F filing with ...
Humira: the highs and lows of the world’s best-selling drug
Pharmaceutical Technology via Yahoo Finance· 3 days agoHumira, an arthritis medication with indications for colitis and psoriasis is the world’s...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Garde Capital Inc.
ETF DAILY NEWS· 6 days agoGarde Capital Inc. lowered its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 60.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm ...
Amgen Inc. (NASDAQ:AMGN) Sees Significant Drop in Short Interest
ETF DAILY NEWS· 4 days agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) was the recipient of a large decrease in short interest in May. As of May 31st, there was short interest totalling 9,050,000 shares, a decrease of ...
Certain Clinical Factors Tied to Poor Response to Biologics for Psoriasis
MedPage Today· 4 days agoPrevious exposure to biologics, higher BMI, smoking all negatively linked to response
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
Bath Savings Trust Co Acquires 196 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 1 day agoBath Savings Trust Co increased its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities ...